Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Amylyx Pharmaceuticals (AMLX) Return on Capital Employed (2022 - 2025)

Amylyx Pharmaceuticals (AMLX) has 4 years of Return on Capital Employed data on record, last reported at 0.47% in Q4 2025.

  • For Q4 2025, Return on Capital Employed fell 14.0% year-over-year to 0.47%; the TTM value through Dec 2025 reached 0.47%, down 14.0%, while the annual FY2025 figure was 0.64%, 44.0% down from the prior year.
  • Return on Capital Employed reached 0.47% in Q4 2025 per AMLX's latest filing, down from 0.37% in the prior quarter.
  • Across five years, Return on Capital Employed topped out at 0.37% in Q3 2025 and bottomed at 1.15% in Q3 2024.
  • Average Return on Capital Employed over 4 years is 0.37%, with a median of 0.39% recorded in 2023.
  • Peak YoY movement for Return on Capital Employed: plummeted -113bps in 2024, then soared 152bps in 2025.
  • A 4-year view of Return on Capital Employed shows it stood at 0.84% in 2022, then soared by 111bps to 0.09% in 2023, then crashed by -446bps to 0.33% in 2024, then crashed by -44bps to 0.47% in 2025.
  • Per Business Quant database, its latest 3 readings for Return on Capital Employed were 0.47% in Q4 2025, 0.37% in Q3 2025, and 0.29% in Q2 2025.